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Chronic obstructive pulmonary disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is one of the major health problems 
to induce morbidity and mortality. Based on the estimates from the World Health 
Organization, 65 million people have moderate to severe COPD all over the world. It 
is predicted that COPD will become the third leading cause of death (~ 8.3 million) 
and the fifth leading cause of disability by 2030 (Barnes, 2000; Laudette et al., 2018). 
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines, COPD is characterized by progressive and not fully reversible airflow 
limitation. Obstruction of small airways, emphysema, enlargement of air spaces and 
destruction of lung parenchyma, loss of lung elasticity, closure of small airways, 
fibrosis, inflammation, mucus hypersecretion, and pulmonary hypertension are the 
key features of COPD lung tissue (Barnes, 2000; Giembycz and Maurice, 2014; 
Vogelmeier et al., 2017). Currently, none of the existing medications used to treat 
COPD have been shown to improve the long-term decline of lung function. Therefore, 
novel medications are urgently needed for COPD prevention and treatment. 
Exposure to cigarette smoke (CS) is considered to be the primary cause of COPD. 
Therefore, the most effective way to prevent the development of COPD is smoke 
cessation (Bergeron and Boulet, 2006; Tønnesen, 2013). Additionally, other factors 
including exposure to indoor pollution from biomass fuels and outdoor air pollution 
including occupational dusts particularly in developing countries and genetics may 
also contribute to pathogenesis of COPD (Boswell-Smith and Spina, 2007; 
Vogelmeier et al., 2017; Wang et al., 2018). 
Pathogenesis and pathophysiology of COPD 
COPD is characterized by chronic inflammation and airway obstruction, which is not 
fully reversible (Vogelmeier et al., 2017). The inflammation in COPD most likely 
occurs in peripheral airways (bronchioles) and lung parenchyma (Barnes, 2014). It 
has been shown that patients with severe COPD have infiltration of macrophages 
and CD8+ T cells and an increased number of neutrophils in bronchial-biopsy (Di 
Stefano et al., 1998; O’Shaughnessy et al., 1997). A dramatic increase of 
macrophages and neutrophils has been observed in bronchoalveolar lavage fluid and 
induced sputum (Keatings et al., 1996; Pesci et al., 1998). Moreover, multiple 
inflammatory mediators, including lipids, chemokines, cytokines and growth factors 
also play a crucial role during COPD development (Barnes, 2014; Lamela and Vega, 
2009). Chronic inflammation is able to induce structural alterations and mucus 
hypersecretion, thereby further causing narrowing of small airways and decline in 
lung function. Epithelial cells and macrophages secrete transforming growth factor-β 
(TGF-β), which triggers fibroblast proliferation and thus contributes to tissue 
remodeling (Barnes, 2014). The inflammatory cytokines, proteases and growth 
factors produced by airway smooth muscle cells are associated with remodeling 
process and induce phenotypic changes of smooth muscle from contractile to 
proliferative phenotype (Aghasafari et al., 2018; Chung, 2005). 
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Chapter 1
As cigarette smoke can induce oxidative stress, there is accumulating evidence that 
oxidative stress is involved in COPD (Kirkham and Barnes, 2013; Wang et al., 2018). 
Except for cigarette smoke, exogenous sources of reactive oxygen species (ROS) 
such as air pollutants, or endogenously released ROS from leukocytes and 
macrophages can also induce oxidative stress and break the balance between 
oxidant and antioxidant (Kirkham and Barnes, 2013). The activated immune cells, for 
instance neutrophils and macrophages, are able to release ROS during the 
inflammatory process(Meijer et al., 2013). Endogenously released ROS reacts with 
lipid, protein, DNA, RNA and mitochondrial DNA, thereby, leading to epithelium injury 
and contributing to COPD development (Boukhenouna et al., 2018). 
Fibrosis, which is a key feature in chronic pulmonary diseases, plays a vital role in 
COPD pathogenesis. It has been shown that epithelial-to-mesenchymal transition 
(EMT), which was triggered either by environmental stresses such as oxidative stress 
(Rhyu et al., 2005) or by extracellular mediators such as TGF-β1 (Hackett et al., 
2009), contributed to pulmonary fibrosis (Jolly et al., 2018; Rout-Pitt et al., 2018; 
Sakuma, 2017). EMT was first identified in the 1980s by Greenburg and Hay 
(Greenburg and Hay, 1986). EMT is a process in which epithelial cells gradually lose 
epithelial proteins including E-cadherin, ZO-1, which are responsible for cell-cell 
contact, and undergo transition to a more mesenchymal phenotype as they gain 
mesenchymal markers such as N-cadherin, vimentin and fibronectin (Nieto, 2011; 
Zuo et al., 2019b). Transcription factors involved during EMT process are Snail, Slug, 
Zeb and Twist (Baulida, 2017; Yang et al., 2013). In 2010, Sohal and colleagues 
demonstrated for the first time that the fibroblast protein marker S100A4 was 
significantly increased in cells within reticular basement membrane clefts of smokers 
and COPD patients compared with never-smoking control subjects by 
immunohistochemistry, indicating an active EMT process in the large airway of CODP 
patients which was highly correlated with cigarette smoke exposure (Sohal et al., 
2010). However, the role of cAMP scaffold in TGF-β1/cigarette smoke-induced EMT 
is still unclear. 
Cyclic AMP targeted therapies in COPD 
According to GOLD guidelines, the aim of therapy in COPD is to relieve symptoms, to 
reduce the frequency and severity of exacerbations and to improve health status and 
exercise performance (Vogelmeier et al., 2017). Unfortunately, no existing COPD 
medication has been conclusively shown to modify the long-term clinical outcomes. 
Cyclic AMP (cAMP) has been proven to be a promising target in COPD treatment 
due to its excellent performance on bronchodilation and anti-inflammation which is 
mediated by cAMP/ cAMP-dependent protein kinase A (PKA) and exchange proteins 
activated by cAMP (Epacs) (Dekkers et al., 2013; Oldenburger et al., 2012b; Roscioni 
et al., 2011b, 2011a; Schmidt et al., 2013). Nowadays, medicines used for COPD 
treatment relies mainly on bronchodilator therapy (β2-agonists, anticholinergics and 
theophylline), and on PDE4 inhibitors used in concert with either corticosteroid or 
bronchodilator treatment especially in COPD patients with a high risk of 
exacerbations (Giembycz and Maurice, 2014; Maji et al., 2018; Vogelmeier et al., 
2017; Wang et al., 2018). 
 
Figure 1. Compartmentalised cAMP signaling. Two distinct cAMP pools are shown in the schematic. One cAMP 
pool is generated by an AC anchored at the plasma membrane and activated by a GPCR exposed to the 
extracellular stimulus; the other one is generated by an internalized GPCR in the cytoplasm. PDEs, as key actors 
in limiting the spread of cyclic nucleotides, are responsible for cAMP hydrolysis and hence compartmentalize the 
cyclic nucleotide signal. The AKAP family, which binds to the regulatory subunits of PKA and targets PKA to 
discreet sites/macromolecular complexes, is also indicated in the schematic. GPCR, G-protein coupled receptor; 




The first evidence for a compartmentalized cAMP signaling has been provided in the 
heart more than 40 years ago. Hayes et al. and Buxton et al. demonstrated 
differences in heart contractility when comparing hearts perfused with different 
agonists to activate the cAMP cascade. The force of heart contraction was enhanced 
with β1-adrenoceptor agonist isoproterenol, whereas there was no change in heart 
contractility when activating prostaglandin E1 receptor with PGE1, even though 
cAMP was elevated and soluble PKA activity was also increased in both cases 
(Buxton and Brunton, 1983; Hayes et al., 1979). These findings provided functional 
evidence for the selectivity of cAMP action, indicating a compartmentalized cAMP 
signaling. 
As one of the most important second messengers, cAMP localizes in well-organized 
intracellular signaling microdomains. As shown in Fig 1, cAMP is synthesized from 
adenosine triphosphate, following activation of adenylyl cyclases (ACs) (Omori and 
Kotera, 2007). Subsequently, cAMP binds to specific intracellular effector proteins, 
such as cyclic nucleotide-gated ion channels, PKA and Epacs (Oldenburger et al., 
2012a; Omori and Kotera, 2007). In addition, PDEs, as key actors in limiting the 
spread of cyclic nucleotides, are responsible for cAMP and cGMP hydrolysis and 
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Chapter 1
hence compartmentalize the cyclic nucleotide signal. The superfamily of PDEs is 
composed of 11 families with a distinct substrate specificity, molecular structure and 
subcellular localization (Omori and Kotera, 2007; Zuo et al., 2019a). Each PDE family 
has at least one (e.g. Pde5a) and often multiple coding genes, resulting in the 
mammalian PDE superfamily being composed of more than 21 genes (Omori and 
Kotera, 2007; Page and Spina, 2012). Moreover, most PDE encoding genes have 
distinct promoters, and multiple transcriptional products which are generated by 
alternative splicing, resulting in nearly 100 different PDE messenger RNAs (Conti and 
Beavo, 2007; Otero et al., 2014). In addition, the communication between β2-
adrenoreceptor, cAMP effectors, PDEs and other downstream targets are 
coordinated by A-kinase anchoring proteins (AKAPs) (shown in Fig 1) (Beene and 
Scott, 2007; Carnegie et al., 2009; Han et al., 2015; Poppinga et al., 2014). Members 
of the AKAPs family bind to the regulatory subunits of PKA and target PKA to discreet 
sites/macromolecular complexes, thereby playing a central role in the regulation of 
cAMP compartmentalization (Beene and Scott, 2007). 
Scope of the thesis 
The main objective of this thesis is to explore the role of compartmentalized cAMP 
signaling in the pathogenesis of COPD, focusing on PDE subfamilies and AKAPs. 
Using in vitro, ex vivo and in vivo approaches, we investigate the potential therapeutic 
targets in cAMP signaling pathways and link it with the current therapies available on 
the market. 
In chapter 2, we provide an overview of Epac function and cAMP scaffolds in the 
heart and the lung. We highlight recent studies in heart and lung pertaining to cAMP 
compartmentalization, which provides more insights in understanding the role of 
cAMP scaffolds in different organs. 
In chapter 3, we review the regulation of several PDEs (PDE3, PDE4, PDE5, PDE7 
and PDE8) and demonstrate the roles of their selective inhibitors in chronic 
pulmonary diseases (COPD and asthma). In addition, the combination of different 
PDE inhibitors is also described, thereby providing a more comprehensive overview 
of the up-to-date research findings. 
In chapter 4, we describe a new method to monitor cAMP dynamics in the airway by 
combining Förster resonance energy transfer (FRET) and precision cut lung slices 
(PCLS). Using this novel setup, the effect of cigarette smoke on cAMP hydrolyzing 
enzymes, PDE3 and PDE4, is studied. We show that cigarette smoke upregulates 
the activity and expression of both PDE3 and PDE4, which in turn, induces changes 
of intracellular cAMP dynamics. Moreover, these findings from PCLS are further 
confirmed using human bronchial epithelial cells and airway smooth muscle cells 
transfected with the cAMP biosensor adenovirus, indicating the different strategies in 
epithelial cells and airway smooth muscle cells with cAMP hydrolysis. In addition, 
functional changes of PDE3 and PDE4 after cigarette smoke exposure are examined 
by airway contractility and ciliary beating frequency (CBF) test. This study provides 
strong evidence of the underlying changes induced by cigarette smoke regarding 
PDE3 and PDE4, providing increased impetus towards the development of improved 
dual PDE3/4 inhibitors for clinical use in smoke-related airway diseases. 
In chapter 5, we discuss the scientific and therapeutic value of a recently published 
research paper in American Journal of Respiratory Cell and Molecular Biology “PDE8 
is expressed in human airway smooth muscle and selectively regulates cAMP 
signaling by β2-AR-AC6”. PDE8, an IBMX insensitive PDE, can be inhibited by PF-
04957325, which is a highly potent and selective PDE8 inhibitor developed by Pfizer. 
The role of PDE8 was demonstrated by Johnstone et al. for the first time in human 
airway smooth muscle cells. We highlight the findings on the transcript, protein and 
functional presence of PDE8 and β2-AR-AC6-PDE8 signalosome which is expressed 
in caveolae. 
In chapter 6, we review the recent knowledge about the role of cAMP scaffolds and 
oxidative stress in EMT process. How cAMP scaffolds (PDEs and AKAPs) and their 
distinguished signalosomes in different subcellular compartments may contribute to 
COPD is described here. 
In chapter 7, we investigate the role of cAMP compartments during TGF-β1/ 
cigarette smoke induced EMT by modulating intracellular AKAPs. The contribution of 
PKA-AKAP complexes to EMT process is studied using the peptide st-Ht31, which 
inhibits the interaction between RII subunits of PKA and AKAP. Among more than 50 
members, specific attention focuses on Ezrin, AKAP95 and Yotiao. The role of Ezrin, 
AKAP95 and Yotiao on EMT process is studied by small interfering RNA. 
In chapter 8, the nasal and bronchial brushes and lung tissues from never-smokers, 
ex-smokers and current smokers are used to study the effect of cigarette smoke on 
PDE3 and PDE4 protein expression. In addition, human mRNA is isolated from 
bronchial and nasal brushings of never-smokers and healthy smokers. 
In chapter 9, we provide a summary of our work, give future perspective of cAMP 
studies, and also describe the challenges. 
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